Imaging of large vessel vasculitis with (18)FDG PET: illusion or reality? A critical review of the literature data.
Fluorine-18 fluorodeoxyglucose positron emission tomography ((18)FDG PET) plays a major role in the management of oncology patients. Owing to the singular properties of the glucose tracer, many patients suffering from non-malignant diseases such as inflammatory or infectious diseases may also derive clinical benefit from the appropriate use of metabolic imaging. Large vessel vasculitides such as giant cell arteritis and Takayasu arteritis are other examples that may potentially extend the field of (18)FDG PET indications. The purpose of the present article is to assess the feasibility of metabolic imaging in vasculitis on the basis of the current literature data. In particular, the clinical context and the (18)FDG imaging patterns seen in patients with large vessel vasculitis are analysed in order to identify potential indications for metabolic imaging.
Belhocine
Tarik
T
Department of Nuclear Medicine, A.Z. Middelheim Hospital, 2020 Antwerp, Belgium. tarik.bel@swing.be
Blockmans
Daniel
D
Hustinx
Roland
R
Vandevivere
Johan
J
Mortelmans
Luc
L
D001158:Arteries / Q000000981:diagnostic imaging* / Q000378:metabolism*; D001161:Arteriosclerosis / Q000000981:diagnostic imaging / Q000378:metabolism; D001167:Arteritis / Q000000981:diagnostic imaging* / Q000378:metabolism*; D003937:Diagnosis, Differential; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D013700:Giant Cell Arteritis / Q000000981:diagnostic imaging / Q000378:metabolism; D006801:Humans; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013625:Takayasu Arteritis / Q000000981:diagnostic imaging / Q000378:metabolism; D014055:Tomography, Emission-Computed / Q000379:methods*; D014657:Vasculitis / Q000000981:diagnostic imaging / Q000378:metabolism
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18